Videos

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

James Q. Del Rosso, DO, discusses the recent report of benzene risk in benzoyl peroxide, as well as the need for active antibiotic monitoring in dermatology.

Boiko discusses the annual weeklong summer camp for children and adolescents with skin diseases to make connections, experience camp with the support of volunteer specialists, and find comfort with their condition.

Peter Marinkovich, MD, reflects on the significant growth in advanced therapy development, particularly in rare skin diseases.

The FDA approved the first 2 therapies to treat molluscum contagiosum in the last year. Silver explains how it's provided more than just treatment options.

Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

In this Lungcast segment, Spicer spoke on several treatment-specific biomarkers for lung cancer and discussed the future of lung cancer therapy.

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

Michelle Kittleson, MD, PhD, provides insight into the potential impact of a new risk score for heart transplant allocation as well as the need for more equitable cardiovascular care in the US.

In a new episode of New Insight with Veeral Sheth, MD, a trio of retina specialists host a well-rounded conversation on recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.

This segment of Eichenfield’s interview features a discussion about the recent announcement of a J-Code for the molluscum contagiosum treatment cantharidin.

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

Faricimab showed sustained vision improvements and retinal drying up to 72 weeks for both branch and central RVO in the phase 3 BALATON and COMINO studies.

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.

In this segment of Lungcast, guest Sue Padernacht went further into the topic of mental health and burnout among clinicians, highlighting some ways to address the situation.

This segment of Lungcast guest Sue Padernacht’s discussion involved the very real topic of burnout among clinicians, as well as defining the differences between stress and burnout.

In this discussion, Soung discusses the VISIBLE study results on guselkumab and its design for individuals of diverse skin tones.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

Katie Falloon, MD, discusses findings from the SEQUENCE study, the importance of treatment positioning, and what direct data from head-to-head studies contributes to this understanding.

Shubha Bhat, PharmD, MS, BCACP describes the ELEVATE UC program supporting the FDA approval of etrasimod and the current understanding of treatment positioning between etrasimod and ozanimod.

In this interview, Neal Bhatia, MD, reacts to the FDA’s approval of roflumilast foam as well as the approval’s background and implications for patients with the inflammatory skin condition.